P.058 Reasons for withholding tissue Plasminogen Activator (tPA) administration during the COVID-19 pandemic at a tertiary stroke centre

Background: Stroke is a leading cause of death and disability worldwide, including Canada. Treatments for stroke are time dependent IV tPA acute ischemic decreases the chance at 90 days if given within 4.5 hours symptom onset. The onset Covid-19 pandemic was initially associated with decrease in treatment thrombolysis across North America. These seemed transient, rebound numbers seen other provinces Canada as widespread lockdown orders were lifted. However, not Royal University Hospital (RUH) Saskatoon, Saskatchewan during same period. We will analyze documented reasons why withheld. Methods: conducted retrospective chart review adult patients strokes presenting to RUH from March 2019 –January 2021. received waiver consent Research Ethics Board. Results: 128 met inclusion criteria. Statistical analysis currently ongoing. Conclusions: Initial results suggest that there similar withholding before after pandemic. main include rapidly resolving/resolved symptoms exclusion criterion.